Carol D Hamilton
Overview
Explore the profile of Carol D Hamilton including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
25
Citations
452
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Liu Y, Chen S, Gao J, Zhang Y, Booher K, Ding X, et al.
Infect Dis Poverty
. 2020 May;
9(1):52.
PMID: 32414419
Background: With the second largest tuberculosis (TB) burden globally, China is committed to actively engage in international TB clinical trials to contribute to global TB research. However, lack of research...
2.
Geadas C, Stoszek S, Sherman D, Andrade B, Srinivasan S, Hamilton C, et al.
Tuberculosis (Edinb)
. 2017 Jan;
102:55-67.
PMID: 28061953
RePORT International is a collaborative research network of investigators from multiple countries and institutions with the goal of establishing a bio-repository of specimens and clinical data for the study of...
3.
Hamilton C, Swaminathan S, Christopher D, Ellner J, Gupta A, Sterling T, et al.
Clin Infect Dis
. 2015 Sep;
61Suppl 3:S155-9.
PMID: 26409277
Progress in tuberculosis clinical research is hampered by a lack of reliable biomarkers that predict progression from latent to active tuberculosis, and subsequent cure, relapse, or failure. Regional Prospective Observational...
4.
Reddy E, Njau B, Morpeth S, Lancaster K, Tribble A, Maro V, et al.
BMC Infect Dis
. 2014 Feb;
14:89.
PMID: 24552306
Background: Routine tuberculosis culture remains unavailable in many high-burden areas, including Tanzania. This study sought to determine the impact of providing mycobacterial culture results over standard of care [unconcentrated acid-fast...
5.
Dooley K, Mitnick C, DeGroote M, Obuku E, Hamilton C, Makhene M, et al.
Clin Infect Dis
. 2012 Sep;
56(1):168-9.
PMID: 22990846
No abstract available.
6.
Dooley K, Mitnick C, DeGroote M, Obuku E, Belitsky V, Hamilton C, et al.
Clin Infect Dis
. 2012 May;
55(4):572-81.
PMID: 22615332
Treatment of drug-resistant tuberculosis is hindered by the high toxicity and poor efficacy of second-line drugs. New compounds must be used together with existing drugs, yet clinical trials to optimize...
7.
Velez Edwards D, Tacconelli A, Wejse C, Hill P, Morris G, Edwards T, et al.
PLoS One
. 2012 Mar;
7(2):e32275.
PMID: 22384203
The monocyte chemotactic protein-1 (MCP-1) is a chemokine that plays an important role in the recruitment of monocytes to M. tuberculosis infection sites, and previous studies have reported that genetic...
8.
Holland D, Sanders G, Hamilton C, Stout J
PLoS One
. 2012 Jan;
7(1):e30194.
PMID: 22272302
Background: The optimal treatment for latent multiple-drug resistant tuberculosis infection remains unclear. In anticipation of future clinical trials, we modeled the expected performance of six potential regimens for treatment of...
9.
Holland D, Sanders G, Hamilton C, Stout J
PLoS One
. 2011 Jul;
6(7):e22276.
PMID: 21789248
Rationale: Rifapentine-based regimens for treating latent tuberculosis infection (LTBI) are being considered for future clinical trials, but even if they prove effective, high drug costs may limit their economic viability....
10.
Morris G, Velez Edwards D, Hill P, Wejse C, Bisseye C, Olesen R, et al.
PLoS One
. 2011 Feb;
6(2):e16656.
PMID: 21339808
We examined whether polymorphisms in interleukin-12B (IL12B) associate with susceptibility to pulmonary tuberculosis (PTB) in two West African populations (from The Gambia and Guinea-Bissau) and in two independent populations from...